Portal de Periódicos da CAPES

STAI (Studio Ticlopidina Angina Instabile) PROJECT. TICLOPIDINE -IN UNSTABLE ANGINA

1987; Thieme Medical Publishers (Germany); Linguagem: Inglês

10.1055/s-0038-1644818

2567-689X

Francesco Violi, Claudio Cimminiello, S Chierichetti, M Scatigna, P Rizzon, F Balsano,

Cardiac Valve Diseases and Treatments

The treatment of patients suffering from unstable angina (UA) with antiplatelet drugs is a therapeutic approach that provided interesting results. Patients given aspirin, that inhibits cyclooxigenase pathway (CP) showed a significant reduction of cardiovascularevents. Quite surprisingly sulfinpirazone, that possesses a mechanism of action similar to aspirin, did not influence cardiovascular complications of UA patients. To further investigate the role of platelets in UA patients, we planned to study if ticlopidine (T), that inhibits platelet function by blocking fibrinogen binding to platelets, influences theclinical course of UA. The study will include 1200 randomised patients given conventional therapy with or without T (500 mg/daily). Patients enrolled have to show one ofthe following clinical pictures: 1) angina at rest; 2) "crescendo angina"; 3) new onset angina. Clinical symptoms should be present within 30 days. The follow-up will last6 months. Primary end-point of the study is the incidence of fatal and non-fatal myocardial infarction and of vascular death. Apart from the possible influence of T in the natural course of UA, the study will offer the opportunity to find and incidence pattern of UA cardiovascular complications in Italy.